Tjalling Erkelens, CEO, Bedrocan|Feb 03, 2019 It was difficult to summarize the developing situation in the UK, which means that it will be even harder to do so for all of Europe. Let’s focus on the more general aspects of cannabis regulations in the EU.
The European Approach
Medicinal cannabis in Europe is regulated as a true pharmaceutical product, however not as a true (registered) medicine. The latter requires a full clinical research pathway - such as with Sativex and Epidiolex (UK based GW Pharmaceuticals.) The European countries that allow patients to attain herbal cannabis (dried flower or extracts dissolved in food grade oil) use a unique capacity called ‘compounding pharmacy’. This allows pharmacists to compound specific medicines from ‘Active Pharmaceutical Ingredients’ (API’s). All based upon a real prescription of a medical doctor or specialist.Read the full Article:
Please login or register for free to keep reading. We'll never sell or share your information...but we will send you a weekly newsletter and eventually even more unique direct insight.
Cannabis Economy is a real-time history of legal cannabis. We chronicle how personal and industry histories have combined to provide our current reality.
If you decline, your information won't be tracked when you visit this website. A single cookie will be used to remember your preference not to be tracked. Accept